New drug targets Fuel-Hungry lung cancer cells in phase 2 trial

NCT ID NCT07249372

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated Jun 10, 2026 · Updated 18 times

Summary

This study tests a drug called DRP-104 in people with advanced non-small cell lung cancer that has specific gene changes (NFE2L2 or KEAP1). The drug works by blocking glutamine, a nutrient cancer cells need to grow. The trial aims to see if the drug can shrink tumors or slow the disease after standard treatments have stopped working. About 37 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Columbia University
RECRUITING

New York, New York, 10032, United States

Contact
NYU Langone Health
RECRUITING

New York, New York, 10016, United States

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER